PERIPHERAL T CELL LYMPHOMA

This early-stage trial is testing the safety of a new gene therapy for adults with certain T-cell lymphomas that have returned or not responded to prior treatments. Doctors will collect a patient's own immune cells, genetically modify them in a lab to target a protein (CCR4) foun…

This study is testing whether a stem cell transplant helps keep T cell lymphoma from coming back better than simply watching patients who are already in remission. Researchers will compare two groups: one that receives their own stem cells back after high-dose chemotherapy, and a…

This study is testing if a drug called ruxolitinib can help patients with T-cell lymphoma stay in remission after a stem cell transplant. The drug is taken daily for a year to try to prevent the cancer from coming back and to reduce a dangerous complication where the donor cells …

This study is testing whether a pill called golidocitinib can help keep cancer from coming back in people with peripheral T-cell lymphoma who responded well to their first chemotherapy. It compares the drug to a placebo (sugar pill) in 136 patients who are not getting a stem cell…

This early-stage study is testing a new version of a cancer treatment called CAR-T cell therapy for people whose lymphomas have returned or not responded to standard treatments. Researchers are using pre-made immune cells from healthy donors, modified to better target a protein (…

This study compares two new drug combinations against standard chemotherapy for people newly diagnosed with peripheral T-cell lymphoma, a rare and aggressive blood cancer. Researchers want to see if adding either belinostat or pralatrexate to chemotherapy helps patients live long…

This study is testing whether a new drug called golidocitinib can help control a rare and aggressive type of blood cancer called peripheral T cell lymphoma (PTCL). It will involve about 30 adults who have just been diagnosed and have not yet received treatment. Researchers want t…

This study is testing whether a new combination of two targeted drugs (linperlisib and chidamide) works better and is safer than the standard CHOP chemotherapy for people newly diagnosed with peripheral T-cell lymphoma (PTCL). The trial has two main parts: first finding the best …

This study is testing whether a combination of two drugs, Cidabenamine and Azacitidine, can help prevent cancer from returning in people with high-risk T-cell lymphoma who have already received a stem cell transplant from a donor. The goal is to see if this 'maintenance' therapy …

This study is testing if adding the drug ruxolitinib to the immunotherapy pembrolizumab is safe and can help control several types of lymphoma that have returned or resisted standard chemotherapy. It is for adults with specific T-cell or B-cell lymphomas who have tried at least o…

This early-stage study is testing a new oral medication called HH2853 in adults with advanced cancers that have come back or stopped responding to standard treatments. The main goals are to find a safe and tolerable dose and to see if the drug shows any early signs of helping to …

This program provides the investigational drug selinexor to patients with certain cancers who have run out of standard treatment options and don't qualify for ongoing clinical trials. It allows doctors to request the drug for eligible patients before it receives full regulatory a…

This study aims to find out which of two stem cell transplant procedures works better for patients with a type of blood cancer called peripheral T-cell lymphoma. The cancer must have partially responded to the first round of treatment. Researchers will compare transplants using a…

This early-phase study is testing a new treatment approach for patients with T-cell lymphoma that has returned or stopped responding to standard therapies. Researchers are combining a genetically modified virus designed to attack cancer cells with two immunotherapy drugs that hel…

This study is testing a new cell therapy for adults with a type of T cell lymphoma that has come back or not responded to prior treatments. Doctors take a patient's own immune cells, genetically modify them in a lab to better target the cancer, and then infuse them back into the …

This study is testing whether combining a new drug called golidocitinib with one of two other medications is safe and effective for people whose peripheral T-cell lymphoma has returned or hasn't responded to previous treatments. The trial will involve about 101 adults at multiple…

This study is testing whether an experimental drug called golidocitinib works better than standard treatments for adults with peripheral T-cell lymphoma that has returned or stopped responding to previous therapies. Researchers will compare how long patients live without their ca…

This early-stage study is testing a new drug called CCS1477 (inobrodib) in patients with advanced blood cancers that have returned or stopped responding to standard treatments. The main goals are to check if the drug is safe, what side effects it causes, and if it shows signs of …

This is an early-stage study testing a new intravenous drug called ST-001 for people with T-cell lymphoma that has come back or not responded to prior treatments. The main goals are to find the highest safe dose and understand how the drug works in the body. It is for adults whos…

This study is observing how doctors in China currently treat patients with peripheral T-cell lymphoma (PTCL), a rare type of blood cancer, in real hospital settings. Researchers will follow 3,000 patients to understand which treatments work best, what side effects occur, and how …

This study aims to understand how a cancer drug called venetoclax works in the body when it's given as a liquid made from crushed tablets. It will enroll up to 30 children and young adults with blood cancers who are already receiving this liquid form because they cannot swallow p…